Факторы риска развития трехкомпонентного поражения органов-мишеней у больных гипертонической болезнью трудоспособного возраста и оценка эффективности различных подходов к инициирующей антигипертензивн
По данным Российского регистра по АГ в 2008 году у каждого четвертого-пятого гипертоника в зависимости от степени повышения АД в дебюте регистрируется поражение органов-мишеней, что значительно увеличивает риск сердечно-сосудистых событий. Данные о частоте встречаемости многокомпонентного ремоделирования органов-мишеней при АГ, особенно у лиц трудоспособного возраста отсутствуют. Изучение этого… Читать ещё >
Содержание
- СПИСОК СОКРАЩЕНИЙ
ГЛАВА 1. ОБЗОР ЛИТЕРАТУРЫ. АНАЛИЗ ЧАСТОТЫ ПОРАЖЕНИЯ ОРГАНОВ-МИШЕНЕЙ ПРИ ГИПЕРТОНИЧЕСКОЙ БОЛЕЗНИ У ЛИЦ ТРУДОСПОСОБНОГО ВОЗРАСТА И АНАЛИЗ ВАРИАНТОВ АНТИГИПЕРТЕНЗИВНОЙ ТЕРАПИИ НА ОСНОВЕ СУЩЕСТВУЮЩИХ РЕКОМЕНДАЦИЙ И
1.1. Частота поражения органов-мишеней при гипертонической болезни у лиц трудоспособного возраста в зависимости от метода диагностики
1.2.Частота комбинированного поражения органов-мишеней при гипертонической болезни у лиц трудоспособного возраста в зависимости от метода диагностики
1.3. Варианты инициации антигипертензивной терапии у больных артериальной гипертензией по различным рекомендациям
1.4. Возможности достижения целевого уровня артериального давления в зависимости от подходов и инициации гипертензивной терапии
ГЛАВА 2. МЕТОДЫ ИССЛЕДОВАНИЯ И ОБЪЕМ НАБЛЮДЕНИЙ
2.1. Клиническая характеристика больных
2.2. Особенности клинического обследования
2.2.1. Оценка поражения сердца
2.2.2. Оценка поражения сосудов
2.2.3. Оценка поражения почек
2.2.4. Оценка эффективности терапии
2.3. Методики лечения
2.4. Дизайн исследования
2.4. Статистическая обработка данных
ГЛАВА 3. ФАКТОРЫ РИСКА РАЗВИТИЯ ТРЕХКОМПОНЕНТНОГО ПОРАЖЕНИЯ ОРГАНОВ-МИШЕНЕЙ У БОЛЬНЫХ ГИПЕРТОНИЧЕСКОЙ БОЛЕЗНЬЮ ТРУДОСПОСОБНОГО ВОЗРАСТА
ГЛАВА 4. ОЦЕНКА ДИНАМИКИ РЕГРЕССА НАРУШЕНИЙ СТРУКТУРЫ И ФУНКЦИИ ОРГАНОВ-МИШЕНЕЙ У НЕЛЕЧЕННЫХ БОЛЬНЫХ ГИПЕРТОНИЧЕСКОЙ БОЛЕЗНЬЮ ТРУДОСПОСОБНОГО ВОЗРАСТА, ИМЕЮЩИХ ТРЕХКОМПОНЕНТНОЕ ИХ ПОРАЖЕНИЕ, НА ФОНЕ РАЗЛИЧНЫХ ПОДХОДОВ К ВЫБОРУ АНТИГИПЕРТЕНЗИВНОЙ ТЕРАПИИ
ОБСУЖДЕНИЕ РЕЗУЛЬТАТОВ
ВЫВОДЫ
I ФАКТИЧЕСКИЕ РЕКОМЕНДАЦИИ
Список литературы
- Айвазян С.А., Мхитарян B.C. (1998), Прикладная статистика и основы эконометрики. М., ЮНИТИ.-1022 с.
- Беленков Ю.Н., Оганов Р. Г. Кардиология: национальное руководство М.: ГЭОТАР- Медиа, 2007. — 610.
- Диагностика и лечение артериальной гипертонии. Российские рекомендации (третий пересмотр), РМОАГ, ВНОК. М., 2008.
- Доугерти Кристофер (1997), Введение в эконометрику. Пер. с англ.-М., ИНФРА-М, — XIV, 402 с.
- Кабалава Ж.Д., Котовская Ю. В., Артериальная гипертония: ключи к диагностике и лечению Москва, 2007. 432 с.
- Кобалава Ж.Д., Толкачева В. В. Цереброваскулярные осложнения АГ. Возможности антагонистов рецепторов ангиотензина II. Сердце, т.2, № 4, 2003, стр.165−172
- Лазебник Л.Б., Милюкова О. М., Комиссаренко И. А. Блокаторы рецепторов ангиотензина II. Москва, 2001, 56 с
- Ю.Леонова М. В., Ерофеева С. Б., Быков A.B., Белоусов Ю. Б. Фармакологический анализ антигипертензивной терапии: приемущества фиксированных комбинаций. Кардиология 2008- 1:4350).
- Медик В.А., Токмачев М. С., Фишман Б. Б. Статистика в медицине и биологии: Руководство. В 2-х томах // Под ред. Ю. М. Комарова. T. I. Теоретическая статистика. Медицина: 2000. -412 с.
- Митьков В.В., Сандриков В. А. Клиническое руководство по ультразвуковой диагностике. Т.5. М.: Видар, 1998.
- Моисеев B.C., Кобалава Ж. Д. Кардиоренальный синдром (почечный фактор и повышение риска сердечно-сосудистых заболеваний). Клин фармак тер 2002- 11(3): 16−8.
- Н.Мухин H.A. Снижение скорости клубочковой фильтрации -общепопуляционный маркер неблагополучного прогноза. Тер архив 2007- 6: 5−10.
- Мухин H.A., Моисеев B.C., Кобалава Ж. Д. и др. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Тер. архив 2004- 6: 39 -46 1).
- Национальные рекомендации по профилактике, диагностике и лечению артериальной гипертонии, Москва, 2004
- Остроумова О.Д., Недогода C.B., МамаевВ.И., Шорикова Е. Г. Фармакологические аспекты эффективности ингибиторов ангиотензинпревращающего фермента при артериальной гипертензии и сердечной недостаточности. РМЖ2003- 5: 262−266
- Рекомендации Европейского общества кардиологов «Профилактика сердечно-сосудистых заболеваний в клинической практике» РФ РКЖ, 2012- 4 (96): 42−49.
- Российским рекомендациям ВНОК и РМОАГ «Профилактика, диагностика и лечение артериальной гипертензии» 2008 года
- Рыбакова М.К., Митьков В. В. Эхокардиография в таблицах и схемах. М: Издательский дом Видар М, 2011. — 288.
- Седьмой доклад Объединенного Национального Комитета по предупреждению, распознаванию, оценке и лечению высокого артериального давления (США) JNC (ОНК)-7. Основные положения. Кардиология 2003- № 8.
- Сергиенко В.И., Бондарева И. Б. Математическая статистика в клинических исследованиях. М. Гэотар-мед, 2001. — 256 с.
- Смирнов A.B., Добронравов В. А., Каюков И. Г. Проблема хронической болезни почек в современной медицине. Артериальная гипертензия 2006- 12 (3): 185−193.
- Томилина H.A., Бигбов Б. Т., Эпидемиология хронической недостаточности и новые подходы к классификации и оценке тяжести хронических прогрессирующих заболеваний почек. Тер архив 2005- 6: 87−92.
- Чазова И.Е., Беленков Ю. Н., Ратова Л. Г. и др. От идеи к клинической практике. Первые результаты российского национального исследования оптимального снижения артериального давления (РОСА). Сист гиперт 2004- 2: 18−23. 13. Lithell Н, Hansson L, Skoog
- Чихладзе Н.М., Сивакова O.A., Самедова Х. Ф. и др. Сравнительный анализ антигипертензивной эффективности лозартана и эналаприла (исследование ЭЛЛА). Рационал. фармакотер. в кардиол. 2008- 1: 44−8.
- Шалыюва С.А., Балапова Ю. А., Константинов В. П., АГ: распространенность, осведомленность, прием АГП и эффективность лечения среди населения РФ. РКЖ, 2006 г., 4: 45−50,
- Aaikar C, Eiskjar H, Mulvany M et al. Abnormal structure and function of isolated subcutaneous resistance vessels from essential hypertensive patients despite antihypertensive treatment. J Hypertens 1989- 7: 305−10.
- Anderson K, Odell P, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1999- 121:293−298.
- Angel i F., Verdecchia P., Reboldi G. et al. Calcium channel blockade to prevent stroke in hypertension. Am J Hypertens 2004- 17: 817−22.
- Argenziano L., Trimarco B. Effect of eprosartan and enalapril in the treatment of elderly hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Curr. Med. Res. Opin., 1999, 15, 9−14.
- Bahlmann, F.H., De Groot, K., Mueller, O., Hertel, B., Haller, II. and Fliser, D. (2005) Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension 45: 526−529
- Belletti, D.A., Zacker, C. and Wogen, J. (2010) Effect of cardiometabolic risk factors on hypertension management: a cross-sectional study among 28 physician practices in the United States. Cardiovasc Diabetol 9: 7.
- Bender SR, Devereux RB, Okin PM. Risks of electrocardiography in hypertensive individuals and benefits of treatment-induced regression. Current Cardiovascular Risk Reports 2009- 3: 247−54.
- Bestehorn, K., Wahle, K. and Kirch, W. (2008) Stroke risk screening of adults with hypertension: prospective cross-sectional study in primary care. Clin Drug Investig 28: 281−289
- Blood pressure control: time for action/ P. Lantelme // Arch Cardiovasc Dis. 2009.-Vol. 102(6−7).-P. 465−467.
- Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment—a review/ P. Bramlage, J. Hasford// Cardiovasc Diabetol. 2009. -Vol.27.- P.8−18.
- Bottorff M., Tenero D. Pharmacokinetics of eprosartan in healthy subjects, patients with hypertension, and special populations. Pharmacotherapy, 1999, 19 (4, pt. 2), 73S-78S.
- Bramlage P, Hasford J. Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment a review. Cardiovasc Diabetol 2009- 27: 8−18.
- Bramlage P., Hasford J. Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment—a review// Cardiovasc Diabetol. 2009. -Vol.27.- P.8−18.
- Bramlage, P. Wolf, WP, Stuhr T. Fronk E.M., Erdlenbruch, W., Ketelhut, P. et al. (2010a) Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice. Vase Health Risk Manag 6: 803−811.
- Bramlage, P. Wolf, WP. Fronk, EM, Stuhr, T., Erdlenbruch, W., Wasem, J. et al. Improving quality of life in hypertension management using a fixeddose combination of olmesartan and amlodipine in primary care. Expert Opin Pharmacother 11: 2779−2790.
- Brooks D., Ohlstein E., Ruffolo R. Pharmacology of eprosartan an angiotensin II receptor antagonist: exploring hypothesis from clinical trials. Am. Heart J., 1999, 138, S247-S251.
- Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003- 289: 2560−72.).
- Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 2003- 289: 2560−2572.-
- Cockroft DW, Gault MM. Prediction of creatinine clearance from serum creatinine Nephron 1976- 16:31 -41
- Compliance with the treatment of hypertension: the potential of combination therapy/ S. Erdine // J Clin Hypertens (Greenwich). 2010 -Vol.12(1). — P.40−46.
- Crowley SD, Gurley SB, Herrera MJ, et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A 2006−103:17 985−17 990.
- Dahlof B, Devereux RB, Kjelddsen SE et al. Cardiovascular morbidity and mortality in the LIFE study: a randomized trial against atenolol. Lancet 2002−359:995−1003
- De Gasparo M., Levens N. Does blockade of angiotensin II receptors offer clinical benefits over inhibition of angioten-converting enzyme? Pharmacol Toxicol. 1998- 82: 257−71.
- De La Sierra, A. (2009) Efficacy of olmesartan medoxomil/amlodipine (Olm/Aml) plus amlodipine (Ami) in age definedsubgroups of moderate-to-severe hypertensive patients. J Hypertens 27(Suppl. 4): S131
- De Simone G., Devereux R.B., Koren M.J. et al. Methods for detection of left ventricular hypertrophy: application to hypertensive heart disease//Eur. Heart J. 1993. — Vol. 14(Suppl. D).-P. 8−15.
- Devereux R.B., Reichek N. Echocardiography determination of left ventricular mass in man: anatomic validation of the method. Circulation. 1977- 55: 613−618.
- Dezii CM. A retrospective study of persistence with single-pill combination therapy vs concurrent two-pill therapy in patients with hypertension. Manag Care 2009- 1: 2−6.
- Diet F., Pratt R.E., Berry G.J. et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease // Circulation. 1996. -Vol. 94.-P. 2756−2767.
- Dtising R. Optimizing blood pressure control through the use of fixed combinations. Vase Health Risk Manag 2010- 25 (6): 321−5.
- Dzau V. The renin-angiotensin system in myocardial hypertrophy and failure. Arch Inter Med. 1993- 153:937−42.
- Dzau V., Sasamura H., Hein L. Heterogenity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J Hypertens. 1993- 11 (suppl 3): SI 1-S18.
- Edwards R., Aiyar N., Ohlstein E. et al. Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108 556. J. Pharmacol. Exp. Ther., 1992, 260, 175−181.
- Egan B.M., Zhao Y., Neal Axon R. et al US Trends in prevalence, awareness, treatment, and control of hypertension, 1988−2008// JAMA. -2010.- Vol.303. P.2043−2050.
- Erdine S. Compliance with the treatment of hypertension: the potential of combination therapy. J Clin Hypertens (Greenwich). 2010 -Vol.12 (1). — P.40−46.
- Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010- 376:1903−1909.
- European Heart Network. European Cardiovascular Disease Statistics. 2008 edition.
- Fabia, M.J., Abdilla, N., Oltra, R., Fernandez, C. and Redon, J. (2007) Antihypertensive activity of angiotensin II ATI receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens 25: 1327−1336.
- Fischer M.A., Avorn J. Economic implications of evidence- based prescribing for hypertension: can better care cost less? JAMA 2004- 291: 1850−1856).
- Fliser, D., Buchholz, K. and Haller, LI. (2004) Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 110: 1103−1107.
- Furberg C., Herrington D., Psaty B. Are drugs within a class interchangeable? Lancet, 1999, 35, 1202−1204.
- Ganau A., Saba P. G, Roman M.J. et al. Agein induces left ventricular concentric remodeling in normotensive subjects. J Hypertens 1995- 13: 1818−1822.
- Garsia P., Maieos A. Evaluation of uric acid excretion and blood pressure in patients with essential hypertension treated with eprosartan and losartan. J. Hypertens., 1998, 16 (Sup-1. 2), S316.
- Garvas I., Garvas H. Safety and tolerability of eprosartan. Pharmacotherapy, 1999, 19 (4, Pt. 2), 102S-107S.
- Gillespie, MS- EV Kuklina, MD, PhD- PA Briss, MD- NA Blair, MPH- Y Hong, MD, PhD- From Morbidity & Mortality Weekly Report Vital Signs: Prevalence, Treatment, and Control of Hypertension — United States, 1999−2002 and 2005−2008- 2011).
- Gradman A., Gray J., Maggiacomo F. et al. Evaluation of the novel angiotensin II antagonist, eprosartan, used once daily in patients with systemic hypertension. Clin. Ther. (in press).
- Gradman AH, Basile JN, Carter BL, et al. Combination therapy in hypertension. J Am Soc Hypertens 2010- 4: 42−50.
- Gradman, AH, Basile, JN, Carter, BL, Bakris, GL, Materson, BJ, Black, HR et al. (2010) Combination therapy in hypertension. J Am Soc Hypertens 4: 90−98
- Grass G., Seravalle G., Cattaneo B. et al. Sympathetic activation in obese normotensive subjects. Hypertension, 1995, 25, 560−563.
- Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003- 21: 1011−1053).
- Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Societyof Hypertension (ESH) and the European Society of Cardiology (ESC). J Hypertens 2007- 25 (6): 1105−87.
- Hedner T. Management of hypertension: the advent of a new angiotensin II receptor antagonist. J. Hypertens., 1999, 17 (Suppl. 2), S21-S25.
- Hedner T., Himmelmann A. on behalf of the Eprosartan Multinational Study Group. The efficacy and tolerance of one or two daily doses of eprosartan inessential hypertension. J. Hypertens., 1999, 17, 129−136.
- Hedner T., Himmelmann A. The efficacy and tolerance of one and two daily doses of eprosartan in essential hypertension. J. Hypertens., 1999, 17, 129−136.
- Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement from the American Heart Association. Circulation, 2011.
- Hi liege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002- 106: 1777−1782
- Iacobellis G., Ribaudo M.C., Letoet G. et al. Influence of excess fat on cardiac morphology and function: study in uncomplicated obesity // Obesity Research. 2002. — Vol. 10. — P. 767−773.
- James P.T., Rigby N., Leach R. The obesity epidemic, metabolic syndrome and future prevention strategies // Eur. J. Cardiovasc. Prev. Rehab. 2004. — Vol. 11. — P. 3−8.
- Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004- 19: 2022−31.
- Kang P.M., Landau A.J., Eberhardt R.T., Frishman W. I I. Angiotensin II receptor antagonists: A new approach to blockade of the renin-angiotensin system. Am heart J. 1994- 127:138801.
- Kannel W. Risk stratification in hypertension: new insights from the Framingham study. Am. J. Hypertens., 2000, 13 (1, Pt. 2), 3S-10S.
- Kannel, W.B. (1996) Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 275: 1571−1576.
- Kearney, P.M., Whelton, M., Reynolds, K., Muntner, P., Whelton. P.K. and He, J. (2005) Global burden of hypertension: analysis of worldwide data. Lancet 365: 217−223.
- Klingbeil A.U., Schneider M., Martus P. et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension // Amer. J. Med. 2003. — Vol. 115. — P. 41−46.
- Kovacs S., Tenero D., Martin D. et al. Pharmacokinetics and protein binding of eprosartan in hemodialysis-dependent patients with end-stage renal disease. Phannacotherapy, 1999, 19 (5), 612−619.
- Labios M, Martinez M, Gabriel F et al. Effects of eprosartan on mitochondrial membrane potential and H202 levels in leucocytes in hypertension. J Hum Hypertens 2008- 22 (7): 493−500.
- Laeis, A. and Ammentorp, B. (2009) Efficacy and tolerability of olmesartan medoxomil/amlodipine (Olm/Aml) by baseline hypertension severity subgroup in patients with moderate to severe hypertension. J Hypertens 27(Suppl. 4): S432.
- Lantelme P. Blood pressure control: time for action // Arch Cardiovasc Dis. 2009. — Vol. 102(6−7). — P. 465−467.
- Lantelme P. Blood pressure control: time for action. Arch Cardiovasc Dis 2009- 102 (6−7): 465−67.
- Law, M.R., Wald, N.J., Morns, J.K. and Jordan, R.E. (2003) Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 326: 1427.
- Lee M et al. Presence of baseline prehypertension and risk of incident stroke: A meta-analysis. Neurology 2011 Oct 4- 77:1330.
- Levine B. Effect of eprosartan and enalapril in the treatment of black hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Curr. Med. Res. Opin., 1999, 15, 25−32.
- Levy D., Garrison R.J., Savage D.D. et ai. Prognostic implications of echocardiographicaly determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990- 322: 1561−1566.
- Ligtenberg G., Blankestijn P., Oey P. et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N. Engl. J. Med., 1999,340, 1321−1328.
- Lindholm L.H., Carlberg B., Samuelsson O. Should beta-blockers remain first choice in the treatment of primary hypertension? A metaanalysis. Lancet 2005−366:1545−53
- Mancia G, Grassi G, Giannattasio C, et al. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999−34:724−728.
- Mancia G., DiRienzo M., Parati G. et al. Sympathetic activity, BP variability and end organ damage in hypertenstion. J. Human. Hypertens., 1997, suppl. 1, S3-S8.
- Mancia G., Laurent S., Agabiti-Rosei E., Ambrosioni E., Burnier, M., Kojt (})hjia, MJ et al. (2009) Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 27: 2121−2158.
- Martin DE, DeCherney GS, Ilson BE et al. Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patients with type II diabetes mellitus. J Clin Pharmacol 1997- 37 (2): 155— 9.
- Massie B.M. Analyses of cost effectiveness in the management of essential hypertension: what they can and what they do not teach us. Clin Cardiol 1996- 19(Suppl. 10): 810−816
- Masuo K., Mikami H., Pgiyara T., Tuck M. Sympathetic hyperactivity preceeds hyperinsulinemia and BP elevation in a young nonobese Japanese population. Am. J. Hypertens., 1997, 10, 77−83.
- Messerli, F.H. (2002) Vasodilatory edema: a common side effect of antihypertensive therapy. Curr Cardiol Rep 4: 479−482.
- Milan A, Caserta MA, Avenatti E et al. Anti-hypertensive drugs and left ventricular hypertrophy: a clinical update. Intern Emerg Med 2010- 5 (6): 469−79.
- Nicodeme R., Albessard A., Amar J. et al Poor blood pressure control in general practice: in search of explanations/.// Arch Cardiovasc Dis. -2009. Vol. 102(6−7). — P.477−483.
- Okin PM, Devereux RB, Jern S et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation 2003- 108: 684−90.
- Okin PM, Devereux RB, Jern S et al., for the LIFE Study Investigators. Regression of Electrocardiographic Left Ventricular Hypertrophy During Antihypertensive Treatment and the Prediction of Major Cardiovascular Events. JAMA 2004- 292: 2343−9.
- Oparil S. Newly emerging pharmacological differencies in angiotensin II receptor blockers. Am. J. Hypertens., 2000, 13 (1, Pt. 2), 18S-24S.
- Pals D.T., Massucci F.D., Sipos F., Dennig Jr G.S.A specific compepitive antagonist of the vascular action of angiotensin II. Cirs Res. 1971- 29: 664−12.
- Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, Ferraro A, Chello M, Mastroroberto P, Verdecchia P, et al: Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001, 104(2): 191—196.
- Philipp T, Glazer RD, Wernsing M et al. Initial combination therapy with amlodipine/valsartan compared with monotherapy in the treatment of hypertension. J Am Soc Hypertens. 2011.
- Prince D., De’Oliveira J. et al. Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men. Hypertension, 1997, 30, 240−246.
- PROGRESS Collaborative Study Group. Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individualswith previous stroke or transient ischaemic attack. Lancet 2001- 358: 103 341.
- R., Kazierad D., Tenero D. A review of eprosartan pharmacokinetic and pharmacodynamic drug interaction studies. Pharmacotherapy, 1999, 19 (4, Pt. 2), 79S-85S.
- Ram CV. Angiotensin blockade with eprosartan: vascular and functional implications. Curr Med Res Opin 2007- 23 (5): 5−11.
- Ritz E. New approaches to pathogenesis and management of hypertension. Clin J Am Soc Nephrol 2009- 4:1886−1889.
- Schiffrin E, Deng L, Larochelle P. Effect of beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertens 1994- 23: 83−91.
- Schlaich MP, Sobotka PA, Krum H, et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009−361:932−934
- Schmieder, R.E. and Bohm, M. (2011) Efficacy and safety of olmesartan medoxomil plus amlodipine in age, gender and hypertension severity defined subgroups of hypertensive patients. J Hum Hypertens 25: 354−363.
- Sega K. Efficacy and safety of eprosartan in severe hypertension. Blood Pressure, 1999, 8, 114−121.
- Serap Erdine, MD Blood Pressure Lowering and Beyond in Special Populations 2012−6(1):31 -44
- Shibasaki Y., Masaki H., Nishiue T., Nishikawa M., Matsubara H. et al. Angiotensin II Type 1 Receptor Antagonist, Losartan, Causes Regressionof Left Ventricular Hypertrophy in End-Stage Renal Disease // Nephron. — 2002. — Vol. 90 (3). — P. 256−261.
- Sica D., Hollenberg N. The renal profile of eprosartan. Pharmacotherapy, 1999, 19 (4, Pt. 2), 86S-94S.
- Sigare H.M., Carei R.M. The subtype-2 (AT2) angiotensin receptor regulates renal cyclic guanosine 3', 5'-monophosphate and ATI receptor-mediated prostaglandin E2 production in conscious rats. J Clin Invest. 1996- 97: 1978−82.
- Sihm I, Schroeder AP, Aalkjaer C et al. Normalization of structural cardiovascular changes during antihypertensive treatment with a regimen based on the ACE-Inhibitor perindopril. Blood Pressure 1995- 4: 241−8.
- Smith, R.D., Yokoyama, H., Averill, D.B., Schiffrin, E.L. and Ferrario, C.M. (2008) Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II Receptors. J Am Soc Hypertens 2: 165−172.
- Steiner JF, Ho PM, Beaty BL, et al. Sociodemographic and clinical characteristics are not clinically useful predictors of refill adherence in patients with hypertension. Circ Cardiovasc Qual 0utcomes.2009- 2:451 457.
- T.L., Elliott M.E., Catt K.J. Angiotensin receptors and their reseptors. N Engl J Med. 1996- 334: 1649−54.
- Tarride J.-E., Morgan L., DesMeules M. et.al. A review of the cost of cardiovascular disease. Canadial J Cardiol 2009- 25: 195−202
- Tedeschi-Reiner E, Strozzi M, Skoric B, Reiner Z, Relation of atherosclerotic changes in rational arteries to the extent of coronary artery disease. Am J Cardiol 2005- 96: 1107−1109.
- Tenero D., Martin D., Chaplsky M. et al. Effect of hepatic disease on the pharmacokinetics and plasma protein binding of eprosartan. Pharmacotherapy, 1998, 18,42−50.
- Tenero D., Martin D., Miller A. et al. Effect of age and gender on the pharmacokinetics of eprosartan. Br. J. Clin. Pharmacol., 1998, 46, 267−270.
- The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007, 25: 1105−1187.
- Unger T. Blood pressure lowering and rennin angiotensin system blockade. J. Hypertens, Vol.21, suppl. 6, 2003, p. S3−7
- Unger T., Chung O., Csikos T. et al. Angiotensin receptors. J Hypertens. 1996- 14 (suppl 5): S95-S103.
- Urata H., Boehm K.D., Philip A. et al. Cellular localization and regional distribution of an angiotension II-forming chymase in the heart. J Clin Invest. 1993- 91: 1269−81.
- US Trends in prevalence, awareness, treatment, and control of hypertension, 1988−2008/ B.M. Egan, Y. Zhao, R. Neal Axon et al.// JAMA. 2010. — Vol.303. — P.2043−2050.
- Vakili BA, Okin PM, Devereux RB et al. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001 — 141: 334−41.
- Verdecchia P., Angeli F., Borgioni C. et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis // Amer. J. Hypertension. 2003. — Vol. 16. — P. 11.
- Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009- 122:290−300.
- Ward K., Sparrow D., Landsberg L. et al. Influence of insulin sympathetic nerovus system activity and obesity on BP: the normative aging study. J. Hypertens., 1996, 14 (3), 310−308.
- Weber M. Clinical efficacy of eprosartan. Pharmacotherapy, 1999, 19 (4, Pt. 2), 95S-101S.
- Weycker D, Edelsberg J, Vincze G, et al. Blood pressure control in patients initiating antihypertensive therapy. Ann Pharmacother 2008- 42:169−176.
- White H. et al, Comparison of office and ambulatory blood pressure measurement to assess the angiotensin II receptor antagonist eprosartan. Blood Press. Monitoring, 1996, 1, 45−50.
- Wolf-Maer K.C., Cuper P. S., Banegas JR, Giampaoli S, Hense HW, Joffres M, и др. Распространенность гипертонии и кровяное давление в 6 европейских странах, Канаде и Соединенных Штатах JAMA 2003- 289: 2363−9).
- Yang, W., Chang, J., Kahler, KH, Fellers, Т., Orloff, J., Wu, EQ et al. (2010) Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Curr Med Res Opin 26: 2065−2076.
- Yusuf, S., Teo, KK, Pogue, J., Dyal, L., Copland, I., Schumacher, II. et al. (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358: 1547−1559.
- Zidek W. Preventing end-organ damage in hypertension. What is the significance of the VALUE Study for general practice? MMW Fortschr Med 2004- 8: 27−8.
- Ziesche, R., Petkov, V., Lambers, C., Erne, P. and Block, L.H. (2004) The calcium channel blocker amlodipine exerts its anti-proliferative action via P21 (WAF1/CIP1) gene activation. FASEB J 18: 1516−1523.